Remission is possible with NeuroStar TMS Therapy®

Clinical Results

NeuroStar® is the only TMS system with the largest, rigorous clinical data set in depression. Many patients treated with NeuroStar TMS Therapy experience significant benefits.

In 2 multisite, randomized, controlled studies, NeuroStar demonstrated clinically significant antidepressant effects7,8

  • Active TMS therapy was superior to sham TMS (placebo) at Week 4 of treatment (P=0.038)7*
  • Significantly more patients achieved remission on active TMS therapy vs sham TMS (P=0.02)8

In open-label clinical trials, after 4 to 6 weeks of treatment9,10

  • 1 in 2 patients improved significantly
  • 1 in 3 patients were free of depression symptoms

Two open-label extension studies demonstrated results consistent with controlled clinical trials.  Some patients may receive benefit from extended therapy for up to 12 weeks.10,11 One prospective, naturalistic study confirmed clinical study results in real-world practice settings with consistent response and remission rates across a broad range of treatment resistance.9

Durability of treatment was demonstrated in an open-label, long-term (6-month) follow-up study, with only an 11% relapse rate across all study patients. Additionally, only 37% of patients required reintroduction of TMS, and of those patients, 85% re-achieved clinical benefit.12

These multiple clinical studies with 800 patients demonstrate that NeuroStar TMS Therapy is an effective treatment approach to achieving remission for patients living with depression.7,8,9,13

Learn more about NeuroStar as a safe treatment for depression

*In patients with a baseline MADRS symptom score of ≥20.

MADRS=Montgomery-Asberg Depression Rating Scale.